home / stock / ions / ions articles

IONS Articles, Ionis Pharmaceuticals Inc.

Stock Information
Company Name: Ionis Pharmaceuticals Inc.
Stock Symbol: IONS
Market: NASDAQ
Website: ionispharma.com
Menu
IONS IONS Quote IONS Short IONS News IONS Articles IONS Message Board
Get IONS Alerts

News, Short Squeeze, Breakout and More Instantly...
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session | Benzinga

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) share...
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile | Benzinga

Friday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with...

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder | Benzinga

On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen I...

Ionis, Biogen Down on Ending Development of ALS Drug | Benzinga

Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced t...
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another | Benzinga

Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BII...

Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows | Benzinga

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor for meta...

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines | Benzinga

Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limeli...
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study | Benzinga

Monday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with&...

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential | Benzinga

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) ...

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment | Benzinga

Friday, FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplonte...
Next 10